Background: Antisense oligonucleotide (ASO), an emerging modality in drug research and development, demands accurate and sensitive bioanalysis to understand its pharmacokinetic and pharmacodynamic properties. Results: By combining the advantages of both ligand binding and liquid chromatography-mass spectrometry/tandem mass (LC-MS/MS), hybridization LC-MS/MS methods were successfully developed and validated/qualified in a good lab practice (GLP) environment for the quantitation of an ASO drug candidate in monkey serum, cerebrospinal fluid (CSF) and tissues in the range of 0.5–500 ng/ml. Special treatment of CSF samples was employed to mitigate nonspecific binding, improve long-term storage stability and enable the usage of artificial CSF as a more accessible surrogate matrix. The method was also qualified and applied to ASO quantitation in various monkey tissue samples using a cocktail tissue homogenate as a surrogate matrix. Conclusion: This work was the first reported GLP validation and application of ASO bioanalysis using the hybridization LC-MS/MS platform.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA 75(1), 285–288 (1978).
Medline CASGoogle Scholar
2. Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol. Adv. 40, 107502 (2020).
Medline CASGoogle Scholar
3. Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14(1), 9–21 (2018).
Medline CASGoogle Scholar
4. Scoles DR, Pulst SM. Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biol. 15(6), 707–714 (2018).
MedlineGoogle Scholar
5. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
Medline CASGoogle Scholar
6. Norris DA, Post N, Yu RZ, Greenlee S, Wang Y. Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics. Bioanalysis 11(21), 1909–1912 (2019). • General review of antisense oligonucleotides bioanalysis using different platforms.
CASGoogle Scholar
7. Wang L. Oligonucleotide bioanalysis: sensitivity versus specificity. Bioanalysis 3(12), 1299–1303 (2011). • General review of antisense oligonucleotides bioanalysis using different platforms.
CASGoogle Scholar
8. Tremblay GA, Oldfield PR. Bioanalysis of siRNA and oligonucleotide therapeutics in biological fluids and tissues. Bioanalysis 1(3), 595–609 (2009).
CASGoogle Scholar
9. Basiri B, Bartlett MG. LC-MS of oligonucleotides: applications in biomedical research. Bioanalysis 6(11), 1525–1542 (2014).
CASGoogle Scholar
10. van Dongen WD, Niessen WM. Bioanalytical LC-MS of therapeutic oligonucleotides. Bioanalysis 3(5), 541–564 (2011).
CASGoogle Scholar
11. Sutton JM, Kim J, El Zahar NM, Bartlett MG. Bioanalysis and biotransformation of oligonucleotide therapeutics by liquid chromatography-mass spectrometry. Mass Spectrom. Rev. 40(4), 334–358 (2021).
Medline CASGoogle Scholar
12. Li P, Gong Y, Kim J et al. Hybridization liquid chromatography-tandem mass spectrometry: an alternative bioanalytical method for antisense oligonucleotide quantitation in plasma and tissue samples. Anal. Chem. 92(15), 10548–10559 (2020). • Development and optimization of hybridization liquid chromatography/mass spectrometry methods.
Medline CASGoogle Scholar
13. Basiri B, Sutton JM, Hooshfar S, Byrnes CC, Murph MM, Bartlett MG. Direct identification of microribonucleic acid miR-451 from plasma using liquid chromatography mass spectrometry. J. Chromatogr. A 1584, 97–105 (2019).
Medline CASGoogle Scholar
14. Dillen L, Sips L, Greway T, Verhaeghe T. Quantitative analysis of imetelstat in plasma with LC-MS/MS using solid-phase or hybridization extraction. Bioanalysis 9(23), 1859–1872 (2017).
CASGoogle Scholar
15. Sips L, Ediage EN, Ingelse B, Verhaeghe T, Dillen L. LC-MS quantification of oligonucleotides in biological matrices with SPE or hybridization extraction. Bioanalysis 11(21), 1941–1954 (2019).
CASGoogle Scholar
16. Guimaraes G, Yuan L, Li P. Antisense oligonucleotide in vitro protein binding determination in plasma, brain, and cerebral spinal fluid using hybridization LC-MS/MS. Drug Metab. Dispos. 50(3), 268–276 (2022).
Medline CASGoogle Scholar
17. US FDA. Bioanalytical method validation guidance for industry. (2018). www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry
Google Scholar
18. European Medicines Agency: guideline on bioanalytical method validation. (2011). www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
Google Scholar
19. Kim J, Basiri B, Hassan C et al. Metabolite profiling of the antisense oligonucleotide eluforsen using liquid chromatography-mass spectrometry. Mol. Ther. Nucleic Acids 17, 714–725 (2019).
Medline CASGoogle Scholar
20. Turnpenny P, Rawal J, Schardt T et al. Quantitation of locked nucleic acid antisense oligonucleotides in mouse tissue using a liquid-liquid extraction LC-MS/MS analytical approach. Bioanalysis 3(17), 1911–1921 (2011).
CASGoogle Scholar
21. Woolf EJ, McDougall S, Fast DM et al. Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teams. AAPS J. 16(5), 885–893 (2014).
Medline CASGoogle Scholar
22. King K, Li P, Pietrasiewicz A, Goldstein S. Perspectives on updates, clarifications and controversies in chromatographic assay guidance for bioanalytical method validation from major regulatory agencies and organizations. Biomed. Chromatogr. 35(1), e5030 (2021).
Medline CASGoogle Scholar
23. Crooke ST, Graham MJ, Zuckerman JE et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277(2), 923–937 (1996).
Medline CASGoogle Scholar
24. Weidolf L, Björkbom A, Dahlén A et al. Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates. Drug Discov. Today 26(10), 2244–2258 (2021).
Medline CASGoogle Scholar
25. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2198–2207 (2009).
Medline CASGoogle Scholar
26. Nguyen JM, Gilar M, Koshel B et al. Assessing the impact of nonspecific binding on oligonucleotide bioanalysis. Bioanalysis 13(16), 1233–1244 (2021).
CASGoogle Scholar
27. Fogh JR, Jacobsen AM, Nguyen T, Rand KD, Olsen LR. Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid. Anal. Bioanal. Chem. 412(7), 1653–1661 (2020).
Medline CASGoogle Scholar
28. Korecka M, Waligorska T, Figurski M et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J. Alzheimer's Dis. 41(2), 441–451 (2014).
Medline CASGoogle Scholar
29. Sidhu R, Jiang H, Farhat NY et al. A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid. J. Lipid Res. 56(6), 1222–1233 (2015).
Medline CASGoogle Scholar
30. Neubert H, Fountain S, King L et al. Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD. Bioanalysis 4(21), 2589–2604 (2012).
CASGoogle Scholar

Vol. 14, No. 9

Supplemental Materials

Metrics

Downloaded 850 times

History

Received 21 January 2022

Accepted 21 April 2022

Published online 12 May 2022

Published in print May 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.future-science.com/doi/suppl/10.4155/bio-2022-0015

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download